HER2会成为晚期尿路上皮癌中新型NECTIN4吗？
Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?
作者信息
Nally Elizabeth, Young Matthew, Wells Connor, Fairhead Rory, Baines Katherine, Cheney-Lowe Hannah, Jackson-Spence Francesca, Powles Thomas
机构信息
Barts Cancer Institute, Queen Mary University of London, London, UK.
Barts Cancer Institute, Queen Mary University of London, London, UK.
出版信息
Eur Urol Focus. 2024 Mar;10(2):219-221. doi: 10.1016/j.euf.2024.05.018. Epub 2024 Jun 1.
PMID:38825408
Abstract
Antibody-drug conjugates have transformed treatment for urothelial cancer (UC). Enfortumab vedotin is the new standard of care in the first-line setting for advanced UC. A personalised approach targeting HER2 in UC is currently being explored.
摘要
抗体药物偶联物已经改变了尿路上皮癌（UC）的治疗方式。恩杂鲁胺是晚期UC一线治疗的新标准。目前正在探索一种针对UC中HER2的个性化治疗方法。
Zotero 插件